Shares of Liquidia surged as much as 44% in pre-market trading on October 14 after the company announced a sweeping settlement with United Therapeutics that ends years of courtroom combat. LQDA jumped 42% following the announcement of a $380.7 million settlement resolving six pending lawsuits and securing the continued commercialization of its lead product, an inhaled treatment for pulmonary arterial hypertension. The stock moved from $26.81 to $38.54, adding roughly $1 billion to Liquidia's market value overnight. The question now: does the math actually work?
The Lawsuits Were the Biggest Risk on the Books — Now They're Gone. The settlement follows a September 30 ruling by a Delaware federal court that upheld certain United Therapeutics patents. Liquidia accepted the ruling without appeal and agreed to strip a secondary lung-disease indication from its product's label.
Removing this legal overhang lets the company focus on commercial execution and pipeline development. Wall Street had been pricing in a worst case — a potential injunction that could have pulled the drug off the market entirely.
$381 Million Is Steep, But the Payment Plan Buys Time. The bill comes in installments: an initial $175 million within 30 business days, two payments of $72.7 million each by early 2027, and a $60.3 million antitrust-related payment.
With $396.1 million in cash as of September 30, the company says it can cover the tab from existing reserves and ongoing sales without raising new capital — meaning no dilution for shareholders, at least for now.
Sales Momentum Is Doing the Heavy Lifting. Quarterly product sales have climbed relentlessly since launch: $51.7 million (Q3 2025), $90.1 million (Q4 2025), $129.9 million (Q1 2026), and $170.4 million (Q2 2026).
Preliminary Q3 2026 sales of $222.7 million continue that streak , implying an annualized run rate near $890 million. Analysts had pegged roughly $210 million per quarter in the back half to hit the $725 million full-year consensus — Liquidia just blew past that.
Losing the Secondary Indication Narrows the Runway. United Therapeutics' competing inhalation products remain approved for both PAH and the secondary lung disease. The settlement preserves Liquidia's core PAH business but surrenders the other indication entirely. That caps Liquidia's addressable market and leaves it more dependent on a single commercial franchise. With roughly 89.5 million shares outstanding , the post-surge market cap sits near $3.5 billion — demanding sustained double-digit sales growth to justify the price.